Tuberculosis (TB)

Policy statements

TB diagnostics and laboratory strengthening

The landscape of TB diagnostics continues to evolve, with new technologies at various stages in the product development pipeline. WHO follows a systematic process for development of policy recommendations, involving synthesis of the available data through systematic reviews, assessment of the evidence by a Guideline Development Group using the GRADE approach, and development of policy guidance for dissemination to Member States and other stake holders.

Guideline Development Group Meeting

WHO convened a Guideline Development Group (GDG) WebEx meeting in Geneva, Switzerland on 23 August 2016 to review evidence on the use of Xpert MTB/RIF for potential update of WHO policy. More details regarding the meeting, the list of participants and their bio-data are available here:

Xpert MTB/RIF Ultra

The use of molecular line probe assays for the detection of resistance to isoniazid and rifampicin

The use of loop-mediated isothermal amplification (TB-LAMP) for the diagnosis of pulmonary tuberculosis

The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs

Framework for implementing TB diagnostics

LF-LAM assay


Framework for indicators and targets for laboratory strengthening under the End TB Strategy


Line probe assays (LPA)


Culture and drug susceptibility testing (DST)

Interferon-gamma release assays (IGRAs)

Commercial serodiagnostic tests

Organization and management

Definitions and reporting